A2B543 / A2 Biotherap - LARVOL DELTA

A2 Biotherapeutics Announces FDA Clearance of IND for A2B543 for Treatment of Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors that Express Mesothelin and Have Lost HLA-A*02 Expression (A2 Bio Press Release) - "It will be evaluated as a second arm of the EVEREST-2 master protocol (NCT06051695) in patients with colorectal cancer, pancreatic cancer, non-small cell lung cancer, ovarian cancer, mesothelioma, and other solid tumors that express mesothelin (MSLN) and have lost HLA-A*02 expression."

IND • Colorectal Cancer • Mesothelioma • Non Small Cell Lung Cancer • Ovarian Cancer • Pancreatic Cancer